Science Foundation Arizona (SFAz) encourages Community College Hispanic Serving Institutions (HSIs) that meet eligibility requirements to apply for Cohort 3 of the KickStarter Program with support by National Science Foundation (NSF HRD# 1450061).
It is well-recognized that patients receiving carboplatin as second-line treatment of ovarian. cancer have at least a modest risk for experiencing hypersensitivity reactions.1 The onset of. reactions is unpredictable and they could occur immediately upon initiation of the drug infusion. or may not be seen until one half or more of the infusion has been administered to the patient. On the other hand, the onset of the reactions has also been reported in patients receiving more. than six cumulative courses. The symptoms associated with the reactions range from a minor. rash to diffuse erythroderma, pruritis, severe anxiety, dyspnea, tachycardia, hypotension, and in. severe cases, death.
The cellular events that result in delayed hypersensitivity reactions primarily involve T cells and macrophages. First, local immune and inflammatory responses at the site of foreign antigen up-regulate endothelial cell adhesion molecule expression, promoting the accumulation of leukocytes at the tissue site.elayed hypersensitivity is a major mechanism of defense against various intracellular pathogens, including mycobacteria, fungi, and certain parasites, and it occurs in transplant rejection and tumor immunity. The central role of CD4 + T cells in delayed hypersensitivity is illustrated in patients with AIDS.